Back to Search
Start Over
Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond.
- Source :
- Expert Review of Neurotherapeutics; Aug2022, Vol. 22 Issue 8, p639-653, 15p
- Publication Year :
- 2022
-
Abstract
- Acute behavioral disturbances in psychosis, including agitation, comprise a heterogeneous group of manifestations varying in intensity and duration they last for. They require rapid, non-coercive treatments ranging from verbal de-escalation to the calming effect of pharmacological agents. The treatment goals are reduction of patient suffering and prevention of disease deterioration. Stabilizing rather than sedating is preferred to ensure improved compliance and a stronger therapeutic alliance. Furthermore, animal pharmacology and clinical studies on agitation reveal the robust calming and anxiolytic properties of loxapine. This review covers the pharmacological and clinical history of loxapine along with research developments. It emphasizes the advantages of its multiple formulations ranging from injectable forms and tablets to orally inhaled forms to attain rapid and fine-tuned tranquilization. Rapid tranquillization is achieved within 2–6 hours using liquid orally-consumed loxapine, and within an hour or less with its IM or orally inhaled forms. Loxapine has been adopted in the management of a wide range of acute disturbances, such as agitation in psychosis. In the context of personalized medicine, key cellular and molecular elements of the schizophrenia phenotype were recently shown to be improved with loxapine. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14737175
- Volume :
- 22
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Expert Review of Neurotherapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 159104198
- Full Text :
- https://doi.org/10.1080/14737175.2022.2108706